Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein.

Currently, mass spectrometry-based protein bioanalysis is primarily achieved through monitoring the representative peptide(s) resulting from analyte protein digestion. However, this approach is often incapable of differentiating the measurement of protein analyte from its post-translational modifications (PTMs) and/or potential biotransformation (BTX) products. This disadvantage can be overcome by direct measurement of the intact protein analytes. Selected reaction monitoring (SRM) on triple quadrupole mass spectrometers has been used for the direct measurement of intact protein. However, the fragmentation efficiency though the SRM process could be limited in many cases, especially for high molecular weight proteins. In this study, we present a new strategy of intact protein bioanalysis by high-resolution (HR) full scan mass spectrometry using human lysozyme as a model protein. An HR linear ion-trap/Orbitrap mass spectrometer was used for detection. A composite of isotopic peaks from one or multiple charge states can be isolated from the background and used to improve the signal-to-noise ratio. The acquired data were processed by summing extracted ion chromatograms (EIC) of the 10 most intense isotopic ions of octuply protonated lysozyme. Quantitation of the plasma lysozyme was conducted by utilizing high resolving power and an EIC window fitting to the protein molecular weight. An assay with a linear dynamic range from 0.5 to 500 μg/mL was developed with good accuracy and precision. The assay was successfully employed for monitoring the level of endogenous lysozyme and a potential PTM in human plasma. The current instrumentation limitations and potential advantages of this approach for the bioanalysis of large proteins are discussed.

[1]  Leonid Zamdborg,et al.  The emerging process of Top Down mass spectrometry for protein analysis: biomarkers, protein-therapeutics, and achieving high throughput. , 2010, Molecular bioSystems.

[2]  E. Woolf,et al.  Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. , 2010, Analytical chemistry.

[3]  C. Arnaud PLASTIC ANTIBODIES TARGET PEPTIDE: NANOTECHNOLOGY: Molecularly imprinted nanoparticles remove bee toxin from blood , 2010 .

[4]  Eric Ezan,et al.  Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. , 2009, Bioanalysis.

[5]  N. Sadagopan,et al.  A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. , 2009, Analytical chemistry.

[6]  S. Carr,et al.  Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? , 2008, Clinical chemistry.

[7]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[8]  R. Humerickhouse,et al.  Investigation of the immunogenicity of a protein drug using equilibrium dialysis and liquid chromatography tandem mass spectrometry detection. , 2005, Analytical chemistry.

[9]  Guilong Cheng,et al.  Mass spectrometry of peptides and proteins. , 2005, Methods.

[10]  Eric M Gage,et al.  A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. , 2003, Analytical chemistry.

[11]  Eric M Gage,et al.  Method development for the concentration determination of a protein in human plasma utilizing 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometric detection. , 2003, Rapid communications in mass spectrometry : RCM.

[12]  R. Kuroki,et al.  Evidence for difference in the roles of two cysteine residues involved in disulfide bond formation in the folding of human lysozyme. , 1990, The Journal of biological chemistry.

[13]  A. E. Sippel,et al.  The human lysozyme gene. Sequence organization and chromosomal localization. , 1989, European journal of biochemistry.

[14]  K. Nakahama,et al.  Human lysozyme: sequencing of a cDNA, and expression and secretion by Saccharomyces cerevisiae. , 1988, Biochemical and biophysical research communications.

[15]  G. Vantrappen,et al.  Radioimmunoassay for urinary lysozyme in human serum from leukemic patients. , 1978, Clinical chemistry.